Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
December 4, 2025 Off

Sunbird Bio Presents New Clinical Data Supporting the Accuracy of its Blood-Based Alpha-Synuclein Assay for Parkinson’s Disease Detection

By BusinessWire

– The sunbird αSyn™ assay accurately classified Parkinson’s disease-positive blood samples with 81% accuracy through the direct detection of EV-bound…

December 4, 2025 Off

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

By BusinessWire

Management to meet with investors and potential partners during Biotech Showcase 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or…

December 4, 2025 Off

Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

By BusinessWire

Offering includes Animal Origin-Free Preps, Transfection-Grade Preps and Target Yield with turnaround time starting at four business days for Express…

December 4, 2025 Off

Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel

By BusinessWire

CARMEL, Ind. & LONDON–(BUSINESS WIRE)–#TYK2—Sudo Biosciences, (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase…

December 4, 2025 Off

Parse Biosciences Launches Evercode Whole Blood Fixation

By BusinessWire

New fixation method streamlines blood sample handling for translational research SEATTLE–(BUSINESS WIRE)–Parse Biosciences, a leading provider of accessible and scalable…

December 4, 2025 Off

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

By BusinessWire

An independent Data Safety Monitoring Board (DSMB) confirms EB103’s favorable safety profile with no treatment-related serious adverse events (SAEs) even…

December 4, 2025 Off

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment

By BusinessWire

OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and…

December 4, 2025 Off

NEUPATH HEALTH ANNOUNCES RENEWAL OF NORMAL COURSE ISSUER BID

By BusinessWire

TORONTO–(BUSINESS WIRE)–NeuPath Health Inc. (TSXV:NPTH) (NeuPath or the “Company”) announced today that the TSX Venture Exchange (the “Exchange”) has accepted…

December 4, 2025 Off

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

By BusinessWire

Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers New…

December 4, 2025 Off

MED-EL Cochlear Implant Becomes First FDA-Approved Option for Children Seven Months and Older

By BusinessWire

First and Only Cochlear Implant FDA Approved for Youngest Infant Population DURHAM, N.C.–(BUSINESS WIRE)–#FDAapproval–MED-EL USA announced today that the U.S.…

Posts pagination

Previous 1 2 3 4 … 6,180 Next

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 5, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine